Main results: We appraised 8 RCTs involving 3034 patients that that were in compliance with inclusion and exclusion criterion. Pooled analyses indicated patients receiving haloperidol prophylaxis and placebo or normal saline did not significantly differ in incidence of delirium (relative risk [RR] = 0.90, 95% confidence interval [CI] = 0.70 to 1.15), with TSA inconclusive. Notably, compared with the control group, use of haloperidol significantly decreased the duration of delirium (Mean difference [MD] ?0.94; 95% CI ?1.82 to ?0.06 days),with a marked heterogeneity. Additionally, haloperidol prophylaxis does not significantly affect duration of mechanical ventilation, length of intensive care unit (ICU) stay, length of hospital stay and mortality. In terms of safety profiles, haloperidol was not associated with increased risk for QTc prolongation, extrapyramidal symptoms, or adverse events. GRADE indicated the level of evidence was very low for a benefit from haloperidol prophylaxis.
我們評估了8項(xiàng)隨機(jī)對照試驗(yàn),納入3034例符合標(biāo)準(zhǔn)的患者。綜合分析表明三組分別接受氟哌啶醇預(yù)防,安慰劑,生理鹽水的患者術(shù)后譫妄發(fā)生率沒有顯著差異([RR]:0.90;95%[CI]:0.70-1.15),序貫實(shí)驗(yàn)分析不確定。值得注意的是,與對照組相比,使用氟哌啶醇顯著降低術(shù)后譫妄的持續(xù)時(shí)間([MD]:?0.94;95%[CI]:?1.82-?0.06),但具有明顯的異質(zhì)性。